Ultrasound-planned high-dose-rate prostate brachytherapy: Dose painting to the dominant intraprostatic lesion

Brachytherapy

Volumn 13, Issue 5, 2014, Pages 433-441

  Crook, Juanita ^a   Ots, Ana ^a   Gaztañaga, Miren ^a   Schmid, Matt ^a   Araujo, Cynthia ^a   Hilts, Michelle ^a   Batchelar, Deidre ^a   Parker, Brent ^a   Bachand, François ^a   Milette, Marie Pierre ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Dose painting; High dose rate brachytherapy; Multiparametric MRI; Prostatic neoplasms; US planning

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; HIGH RISK PATIENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY;

DOSE PAINTING; HIGH-DOSE-RATE BRACHYTHERAPY; MULTIPARAMETRIC MRI; PROSTATIC NEOPLASMS; US PLANNING;

ADENOCARCINOMA; AGED; BRACHYTHERAPY; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANS AT RISK; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECTUM; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; URETHRA;

EID: 84906082334     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2014.05.006     Document Type: Article

References (44)

1. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. A dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J.Clin.Oncol 2006, 24:1990-1996.
2. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487. 10.1016/S1470-2045(07)70143-2.
3. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111. 10.1200/JCO.2009.25.8475.
4. Beckendorf V., Guerif S., Le Prise E., et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80:1056-1063. 10.1016/j.ijrobp.2010.03.049.
5. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74. 10.1016/j.ijrobp.2007.06.054.
6. Zelefsky M.J., Reuter V.E., Fuks Z., et al. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008.
7. Stone N.N., Stone M.M., Rosenstein B.S., et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 2011, 185:495-500. 10.1016/j.juro.2010.09.099.
8. Pucar D., Hricak H., Shukla-Dave A., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: Magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007, 69:62-69. 10.1016/j.ijrobp.2007.03.065.
9. Arrayeh E., Westphalen A.C., Kurhanewicz J., et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012, 82:e787-e793. 10.1016/j.ijrobp.2011.11.030.
10. Ling C.C., Humm J., Larson S., et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000, 47:551-560.
11. Thorwarth D., Eschmann S.M., Paulsen F., et al. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007, 68:291-300. 10.1016/j.ijrobp.2006.11.061.
12. Bentzen S.M. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 2005, 6:112-117. 10.1016/S1470-2045(05)01737-7.
13. Groenendaal G., Borren A., Moman M.R., et al. Pathologic validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for tumor delineation in the prostate peripheral zone. Int J Radiat Oncol Biol Phys 2012, 82:e537-e544. 10.1016/j.ijrobp.2011.07.021.
14. Groenendaal G., van den Berg C.A., Korporaal J.G., et al. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol 2010, 95:185-190. 10.1016/j.radonc.2010.02.014.
15. van Lin E.N., Futterer J.J., Heijmink S.W., et al. IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006, 65:291-303. 10.1016/j.ijrobp.2005.12.046.
16. Jouyaux F., De Crevoisier R., Manens J.P., et al. High dose for prostate irradiation with image guided radiotherapy: Contribution of intensity modulation arctherapy. Cancer Radiother 2010, 14:679-689. 10.1016/j.canrad.2010.03.003.
17. Maggio A., Fiorino C., Mangili P., et al. Feasibility of safe ultra-high (EQD(2)>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotherapy. Acta Oncol 2011, 50:25-34. 10.3109/0284186X.2010.530688.
18. Kobus T., Vos P.C., Hambrock T., et al. Prostate cancer aggressiveness: Invivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. Radiology 2012, 265:457-467. 10.1148/radiol.12111744.
19. Lunacek A., Simon J., Bernt R., et al. Increased rate of positive biopsies using a combination of MR-Tomography, spectroscopy and diffusion-weighted magnetic resonance imaging prior to prostate biopsies in patients with persistent elevated prostate-specific antigen values: A retrospective analysis. Urol Ann 2013, 5:76-80. 10.4103/0974-7796.110001.
20. Javali T.D., Dwivedi D.K., Kumar R., et al. Magnetic resonance spectroscopy imaging-directed transrectal ultrasound biopsy increases prostate cancer detection in men with prostate-specific antigen between 4-10 ng/mL and normal digital rectal examination. Int J Urol 2013, 10.1111/iju.12258.
21. Ganie F.A., Wani M.S., Shaheen F., et al. Endorectal coil MRI and MR-spectroscopic imaging in patients with elevated serum prostate specific antigen with negative trus transrectal ultrasound guided biopsy. Urol Ann 2013, 5:172-178. 10.4103/0974-7796.115741.
22. Brame R.S., Zaider M., Zakian K.L., et al. Regarding the focal treatment of prostate cancer: Inference of the Gleason grade from magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2009, 74:110-114. 10.1016/j.ijrobp.2008.07.055.
23. Galalae R.M., Martinez A., Nuernberg N., et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?. Strahlenther Onkol 2006, 182:135-141. 10.1007/s00066-006-1448-5.
24. Batchelar D., Gaztanaga M., Schmid M., et al. Validation study of ultrasound-based high-dose-rate prostate brachytherapy planning compared with CT-based planning. Brachytherapy 2014, 13(1):75-79. 10.1016/j.brachy.2013.08.004.
25. Aluwini S., van Rooij P.H., Kirkels W.J., et al. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naive low- and intermediate-risk prostate cancer: A 7-year experience. Int J Radiat Oncol Biol Phys 2012, 83:1480-1485. 10.1016/j.ijrobp.2011.10.055.
26. Martinez A.A., Gonzalez J., Ye H., et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:363-370. 10.1016/j.ijrobp.2009.10.035.
27. Martinez A., Gonzalez J., Spencer W., et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 2003, 169:974-979. discussion 979-980. 10.1097/01.ju.0000052720.62999.a9.
28. Bachand F., Martin A.G., Beaulieu L., et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: Biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009, 73:679-684. 10.1016/j.ijrobp.2008.05.003.
29. Demanes D.J., Martinez A.A., Ghilezan M., et al. High-dose-rate monotherapy: Safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:1286-1292. 10.1016/j.ijrobp.2010.10.015.
30. Yamada Y., Bhatia S., Zaider M., et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 2006, 5:157-164. 10.1016/j.brachy.2006.03.004.
31. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int JRadiat Oncol Biol Phys 2008, 71:1028-1033. 10.1016/j.ijrobp.2007.11.066.
32. Valicenti R.K., Bae K., Michalski J., et al. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys 2011, 79:1323-1329. 10.1016/j.ijrobp.2010.01.009.
33. Bentzen S.M., Dorr W., Gahbauer R., et al. Bioeffect modeling and equieffective dose concepts in radiation oncology-terminology, quantities and units. Radiother Oncol 2012, 105:266-268. 10.1016/j.radonc.2012.10.006.
34. Fowler J.F. The radiobiology of prostate cancer including new aspectsof fractionated radiotherapy. Acta Oncol 2005, 44:265-276. 10.1080/02841860410002824.
35. Abe E., Mizowaki T., Norihisa Y., et al. Impact of multileaf collimator width on intraprostatic dose painting plans for dominant intraprostatic lesion of prostate cancer. J Appl Clin Med Phys 2010, 11:3193.
36. Turkbey B., Pinto P.A., Mani H., et al. Prostate cancer: Value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010, 255:89-99. 10.1148/radiol.09090475.
37. Brix G., Griebel J., Kiessling F., et al. Tracer kinetic modelling oftumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging 2010, 37(Suppl 1):S30-S51. 10.1007/s00259-010-1448-7.
38. Pouliot J., Kim Y., Lessard E., et al. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004, 59:1196-1207. 10.1016/j.ijrobp.2004.02.055.
39. Kazi A., Godwin G., Simpson J., et al. MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer. BMC Cancer 2010, 10:472. 10.1186/1471-2407-10-472.
40. Logan J.K., Rais-Bahrami S., Turkbey B., et al. Current status of MRI and ultrasound fusion software platforms for guidance of prostate biopsies. BJU Int 2013, 10.1111/bju.12593.
41. Chabanova E., Balslev I., Logager V., et al. Prostate cancer: 1.5 T endo-coil dynamic contrast-enhanced MRI and MR spectroscopy-Correlation with prostate biopsy and prostatectomy histopathological data. Eur J Radiol 2011, 80:292-296. 10.1016/j.ejrad.2010.07.004.
42. Gaudet M., Vigneault E., Aubin S., et al. Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: A prospective comparative toxicity analysis. Int J Radiat Oncol Biol Phys 2010, 77:153-159. 10.1016/j.ijrobp.2009.04.049.
43. Kim Y., Hsu I.C., Lessard E., et al. Class solution in inverse plannedHDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI. Radiother Oncol 2008, 88:148-155. 10.1016/j.radonc.2007.11.024.
44. Ippolito E., Mantini G., Morganti A.G., Mazzeo E., Padula G.D., Digesù C., Cilla S., Frascino V., Luzi S., Massaccesi M., Macchia G., Deodato F., Mattiucci G.C., Piermattei A., Cellini N. Am J Clin Oncol 2012, 35(2):158-162. 10.1097/COC.0b013e318209cd8f.